PITTSBURGH--(BUSINESS WIRE)--Precision Therapeutics has released the results of a study that determines whether ChemoFx® results change from primary diagnosis to recurrence of disease in gynecological tumors with intervening administration of adjuvant chemotherapy. ChemoFx®is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician.
